公开(公告)号：EP4397762A1

公开(公告)日：2024-07-10

申请号：EP22864537.0

申请日：2022-08-30

申请人： Taisho Pharmaceutical Co., Ltd.

发明人： KUROKAWA, Tomofumi ,  UEMATSU, Yoshikatsu ,  HATA, Tomoyuki ,  ADACHI, Hisashi ,  SUGITA, Ayumi

IPC分类号： C12N15/13 ,  A61K39/395 ,  A61P3/10 ,  A61P5/08 ,  A61P11/00 ,  A61P13/12 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K16/26 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/63 ,  C12P21/08

CPC分类号： A61K39/395 ,  A61P3/10 ,  A61P5/08 ,  A61P13/12 ,  A61P11/00 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07K16/00 ,  C07K16/26 ,  C12N5/10 ,  C12N15/63 ,  C12N15/80 ,  C12N15/81 ,  C12N15/74

摘要： In one embodiment, the present invention provides an antibody specifically binding to human GH or an antigen-binding fragment thereof. In one embodiment, the present invention relates to an antibody specifically binding to human GH or an antigen-binding fragment thereof, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises an amino acid sequence set forth in SEQ ID NO: 5 as a VH complementarity-determining region (CDR) 1 (VHCDR1), an amino acid sequence set forth in SEQ ID NO: 6 as a VHCDR2, and an amino acid sequence set forth in SEQ ID NO: 7 as a VHCDR3, and the VL comprises an amino acid sequence set forth in SEQ ID NO: 8 as a VL complementarity-determining region (CDR) 1 (VLCDR1), an amino acid sequence set forth in SEQ ID NO: 9 as a VLCDR2, and an amino acid sequence set forth in SEQ ID NO: 10 as a VLCDR3.